Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates
PBLS•Pipeline update
- Parabilis Medicines said it is on track to initiate a desmoid tumor Phase 3 trial in the first half of 2027.
Second-quarter financial results and cash position
Aug. 13 (Reuters) - Parabilis Medicines Inc. PBLS.O reported second-quarter 2026 financial results and provided business updates.
- Parabilis Medicines ended the second quarter with $1.10 billion in cash, cash equivalents and marketable securities.
- The company said it expects those resources to fund operations into 2030.
